<DOC>
	<DOCNO>NCT00003105</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy treat patient metastatic locally advanced bladder cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Locally Advanced Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxicity doxorubicin , gemcitabine , filgrastim ( G-CSF ) follow ifosfamide , paclitaxel , cisplatin , G-CSF patient metastatic locally advanced transitional cell carcinoma urothelium . - Determine efficacy regimen patient population . OUTLINE : This dose-escalation study gemcitabine . Patients receive doxorubicin IV 30 minute gemcitabine IV day 1 filgrastim ( G-CSF ) subcutaneously ( SC ) day 3-11 . Treatment repeat every 2 week 5 course . After completion fifth course , patient receive paclitaxel IV 3 hour cisplatin IV 1 hour day 1 , ifosfamide IV 1 hour day 1-3 , G-CSF SC daily day 6-17 . Treatment repeat every 3-4 week 4 course . Cohorts 3-6 patient receive escalate dos gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 3 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient treat MTD . PROJECTED ACCRUAL : A maximum 20 patient accrued phase I maximum 10 patient accrue phase II within 2-3 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma urothelium Measurable disease , define unresectable metastatic urothelial tract tumor OR Evaluable disease , define T3b T4a bladder tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Granulocyte count great 1,500/mm^3 Platelet count great 150,000/mm^3 Hepatic : Bilirubin le 1.5 time normal SGOT le 2 time normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease No serious cardiac arrhythmia , include first , second , third degree heart block LVEF least 50 % Other : No uncontrolled infection No active malignancy except curatively treat nonmelanomatous skin cancer carcinoma situ cervix Fertile patient must use effective barrier contraception , , 6 month study encourage continue 2 year longer study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
</DOC>